# US 2004/0083497 A1 · Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0083497 A1
- Document ID: US20040083497A1
- Status: Published application
- Kind: A1
- Application number: 10/422,571
- Filed: 2003-04-23
- Published: 2004-04-29
- Earliest claimed: 2002-08-16
- Inventors: Arthur B. Raitano; Pia M. Challita-Eid; Aya Jakobovits; Mary Faris; Wangmao Ge
- Web page: https://patentgrep.com/patent/US20040083497A1

## CPC

- C12N 5/0693: {Tumour cells; Cancer cells}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/435: from animals; from humans
- C07K 14/47: from mammals
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2217/075: inducing loss of function, i.e. knock out
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2319/00: Fusion polypeptide
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A novel gene 191P4D12(b) and its encoded protein, and variants thereof, are described wherein 191P4D12(b) exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 191P4D12(b) provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 191P4D12(b) gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P4D12(b) can be used in active or passive immunization.

## Claims

### Claim 1

A composition that comprises, consists essentially of, or consists of:
a) a peptide of eight, nine, ten, or eleven contiguous amino acids of a protein of FIG. 2;
b) a peptide of Tables VIII-XXI;
c) a peptide of Tables XXII to XLV; or,
d) a peptide of Tables XLVI to XLIX.

### Claim 2 (depends on 1)

A composition of claim 1 that comprises a protein related to a protein of FIG. 2.

### Claim 3 (depends on 2)

A protein of claim 2 that is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% homologous to an entire amino acid sequence shown in FIG. 2.

### Claim 4 (depends on 1)

A composition of claim 1 wherein the substance comprises a CTL polypeptide or an analog thereof, from the amino acid sequence of a protein of FIG. 2.

### Claim 5 (depends on 4)

A composition of claim 4 further limited by a proviso that the epitope is not an entire amino acid sequence of FIG. 2.

### Claim 6 (depends on 1)

A composition of claim 1 further limited by a proviso that the polypeptide is not an entire amino acid sequence of a protein of FIG. 2.

### Claim 7 (depends on 1)

A composition of claim 1 that comprises an antibody polypeptide epitope from an amino acid sequence of FIG. 2.

### Claim 8 (depends on 7)

A composition of claim 7 further limited by a proviso that the epitope is not an entire amino acid sequence of FIG. 2.

### Claim 9 (depends on 7)

A composition of claim 7 wherein the antibody epitope comprises a peptide region of at least 5 amino acids of FIG. 2 in any whole number increment up to the end of said peptide, wherein the epitope comprises an amino acid position selected from:
a) an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of FIG. 5,
b) an amino acid position having a value less than 0.5 in the Hydropathicity profile of FIG. 6;
c) an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of FIG. 7;
d) an amino acid position having a value greater than 0.5 in the Average Flexibility profile of FIG. 8;
e) an amino acid position having a value greater than 0.5 in the Beta-turn profile of FIG. 9;
f) a combination of at least two of a) through e);
g) a combination of at least three of a) through e);
h) a combination of at least four of a) through e); or
i) a combination of five of a) through e).

### Claim 10 (depends on 1)

A polynucleotide that encodes a protein of claim 1.

### Claim 11 (depends on 10)

A polynucleotide of claim 10 that comprises a nucleic acid molecule set forth in FIG. 2.

### Claim 12 (depends on 10)

A polynucleotide of claim 10 further limited by a proviso that the encoded protein is not an entire amino acid sequence of FIG. 2.

### Claim 13 (depends on 11)

A composition of claim 11 wherein the substance comprises a polynucleotide that comprises a coding sequence of a nucleic acid sequence of FIG. 2.

### Claim 14 (depends on 1, 11)

A polynucleotide of claim 11 that further comprises an additional nucleotide sequence that encodes an additional peptide of claim 1.

### Claim 15 (depends on 10)

A composition comprising a polynucleotide that is fully complementary to a polynucleotide of claim 10.

### Claim 16

A method of generating a mammalian immune response directed to a protein of FIG. 2, the method comprising:
exposing cells of the mammal's immune system to a portion of
a) a 191P4D12(b)-related protein and/or
b) a nucleotide sequence that encodes said protein,
whereby an immune response is generated to said protein.

### Claim 17 (depends on 16)

A method of generating an immune response of claim 16, said method comprising:
providing a 191P4D12(b)-related protein that comprises at least one T cell or at least one B cell epitope; and,
contacting the epitope with a mammalian immune system T cell or B cell respectively, whereby the T cell or B cell is activated.

### Claim 18 (depends on 17)

A method of claim 17 wherein the immune system cell is a B cell, whereby the induced B cell generates antibodies that specifically bind to the 191P4D12(b)-related protein.

### Claim 19 (depends on 17)

A method of claim 17 wherein the immune system cell is a T cell that is a cytotoxic T cell (CTL), whereby the activated CTL kills an autologous cell that expresses the 191P4D12(b)-related protein.

### Claim 20 (depends on 17)

A method of claim 17 wherein the immune system cell is a T cell that is a helper T cell (HTL), whereby the activated HTL secretes cytokines that facilitate the cytotoxic activity of a cytotoxic T cell (CTL) or the antibody-producing activity of a B cell.

### Claim 21

Amethod for detecting, in a sample, the presence of a 191P4D12(b)-related protein or a 191P4D12(b)-related polynucleotide, comprising steps of:
contacting the sample with a substance that specifically binds to the 191P4D12(b)-related protein or to the 191P4D12(b)-related polynucleotide, respectively; and,
determining that there is a complex of the substance with the 191P4D12(b)-related protein or the substance with the 191P4D12(b)-related polynucleotide, respectively.

### Claim 22 (depends on 21)

A method of claim 21 for detecting the presence of a 191P4D12(b)-related protein in a sample comprising steps of:
contacting the sample with an antibody or fragment thereof either of which specifically bind to the 191P4D12(b)-related protein; and,
determining that there is a complex of the antibody or fragment thereof and the 191P4D12(b)-related protein.

### Claim 23 (depends on 21)

A method of claim 21 further comprising a step of:
taking the sample from a patient who has or who is suspected of having cancer.

### Claim 24 (depends on 21)

A method of claim 21 for detecting the presence of a protein of FIG. 2 mRNA in a sample comprising:
producing cDNA from the sample by reverse transcription using at least one primer;
amplifying the cDNA so produced using 191P4D12(b) polynucleotides as sense and antisense primers, wherein the 191P4D12(b) polynucleotides used as the sense and antisense primers serve to amplify a 191P4D12(b) cDNA; and,
detecting the presence of the amplified 191P4D12(b) cDNA.

### Claim 25 (depends on 21)

A method of claim 21 for monitoring one or more 191P4D12(b) gene products in a biological sample from a patient who has or who is suspected of having cancer, the method comprising:
determining the status of one or more 191P4D12(b) gene products expressed by cells in a tissue sample from an individual;
comparing the status so determined to the status of one or more 191P4D12(b) gene products in a corresponding normal sample; and,
identifying the presence of one or more aberrant gene products of 191P4D12(b) in the sample relative to the normal sample.

### Claim 26 (depends on 25)

The method of claim 25 further comprising a step of determining if there are one or more elevated gene products of a 191P4D12(b) mRNA or a 191P4D12(b) protein, whereby the presence of one or more elevated gene products in the test sample relative to the normal tissue sample indicates the presence or status of a cancer.

### Claim 27 (depends on 26)

A method of claim 26 wherein the cancer occurs in a tissue set forth in Table I.

### Claim 28

A composition comprising:
a substance that a) modulates the status of a protein of FIG. 2, or b) a molecule that is modulated by a protein of FIG. 2, whereby the status of a cell that expresses a protein of FIG. 2 is modulated.

### Claim 29 (depends on 28)

A composition of claim 28, further comprising a physiologically acceptable carrier.

### Claim 30 (depends on 28)

A pharmaceutical composition that comprises the composition of claim 28 in a human unit dose form.

### Claim 31 (depends on 28)

A composition of claim 28 wherein the substance comprises an antibody or fragment thereof that specifically binds to a protein of FIG. 2.

### Claim 32 (depends on 31)

An antibody or fragment thereof of claim 31, which is monoclonal.

### Claim 33 (depends on 31)

An antibody of claim 31, which is a human antibody, a humanized antibody or a chimeric antibody.

### Claim 34 (depends on 31)

A non-human transgenic animal that produces an antibody of claim 31.

### Claim 35 (depends on 32)

A hybridoma that produces an antibody of claim 32.

### Claim 36 (depends on 4)

A method of delivering a cytotoxic agent or a diagnostic agent to a cell that expresses a protein of FIG. 2, said method comprising:
providing the cytotoxic agent or the diagnostic agent conjugated to an antibody or fragment thereof of claim 4; and,
exposing the cell to the antibody-agent or fragment-agent conjugate.

### Claim 37 (depends on 28)

A composition of claim 28 wherein the substance comprises a polynucleotide that encodes an antibody or fragment thereof, either of which immunospecifically bind to a protein of FIG. 2.

### Claim 38 (depends on 28)

A composition of claim 28 wherein the substance comprises a) a ribozyme that cleaves a polynucleotide having a 191P4D12(b) coding sequence, or b) a nucleic acid molecule that encodes the ribozyme; and, a physiologically acceptable carrier.

### Claim 39 (depends on 28)

A composition of claim 28 wherein the substance comprises human T cells, wherein said T cells specifically recognize a 191P4D12(b) peptide subsequence in the context of a particular HLA molecule.

### Claim 40 (depends on 28)

A method of inhibiting growth of cancer cells that express a protein of FIG. 2, the method comprising:
administering to the cells the composition of claim 28.

### Claim 41 (depends on 40)

A method of claim 40 of inhibiting growth of cancer cells that express a protein of FIG. 2, the method comprising steps of:
administering to said cells an antibody or fragment thereof, either of which specifically bind to a 191P4D12(b)-related protein.

### Claim 42 (depends on 40)

A method of claim 40 of inhibiting growth of cancer cells that express a protein of FIG. 2, the method comprising steps of:
administering to said cells a 191P4D12(b)-related protein.

### Claim 43 (depends on 40)

A method of claim 40 of inhibiting growth of cancer cells that express a protein of FIG. 2, the method comprising steps of:
administering to said cells a polynucleotide comprising a coding sequence for a 191P4D12(b)-related protein or comprising a polynucleotide complementary to a coding sequence for a 191P4D12(b)-related protein.

### Claim 44 (depends on 40)

A method of claim 40 of inhibiting growth of cancer cells that express a protein of FIG. 2, the method comprising steps of:
administering to said cells a ribozyme that cleaves a polynucleotide that encodes a protein of FIG. 2.

### Claim 45 (depends on 40)

A method of claim 40 of inhibiting growth of cancer cells that express a protein of FIG. 2 and a particular HLA molecule, the method comprising steps of:
administering human T cells to said cancer cells, wherein said T cells specifically recognize a peptide subsequence of a protein of FIG. 2 while the subsequence is in the context of the particular HLA molecule.

### Claim 46 (depends on 40)

A method of claim 40, the method comprising steps of:
administering a vector that delivers a nucleotide that encodes a single chain monoclonal antibody, whereby the encoded single chain antibody is expressed intracellularly within cancer cells that express a protein of FIG. 2.
